3 days popular7 days popular1 month popular3 months popular

Novel Strategies To Improve Success In Cancer Vaccine Clinical Trials, 19 – 20 September 2012, London, UK

There have so far only been three cancer approved by the FDA, and many others are now nearing the end of their . Two of these were for HPV, which is responsible for 70% of cervical cancer. The most recent, and most exciting is the approval of Provenge last year, which is a vaccine for by Dendreon.

With a successful pathway through the commercialization and regulatory process now mapped out, companies are really starting to increase their work in this field to ensure success in clinical trials.

SMi’s inaugural conference on will provide attendees with a complete view of the difference between clinical development of vaccines and cytotoxic anti-cancer drugs, the cancer immunotherapy field, focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an in depth look into current advances in .

Here’s what , Senior Medical Director and , Merck Serono one of our chairs had to say about this exciting event:

“Active immunotherapy, aiming at the generation of a tumor-specific immune response is gaining momentum.This meeting is an interesting forum to discuss the recent achievements in the field, the future challenges ahead, and the development of new technologies.”

Key benefits of attending

  • Consider novel combination therapies in cancer vaccine development
  • Understand effective immunological targeting processes
  • Evaluate progress in current mRNA vaccine development
  • Discover strategies to improve success and overcome current issues in clinical trials
  • Learn about clinical and regulatory design of immunotherapy programs
  • Discuss lessons learned from interactions with national and international regulatory agencies
  • Hear from the industry on updates on the most recent successful candidates in late phase studies
  • Develop strategies to monitor immunotherapy outcomes
  • Network and learn from key opinion leaders from industry and academia

For more information visit http://www.smi-online.co.uk/cancervaccinesevent72.asp alternatively contact Fateja Begum on +44 0 207 827 6184 or email on [email protected]

Quote MNT and save £100


SMi Group Ltd